Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Faeth Therapeutics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
FTH
Nasdaq
2834
www.faeththerapeutics.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Faeth Therapeutics, Inc.
Faeth Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate PIKTOR in Combination with a Selective Estrogen Receptor Degrader in HR+/HER2- Advanced Breast Cancer
- Nov 16th, 2026 5:00 am
Faeth Therapeutics to Participate in Upcoming November Investor Conferences
- Nov 11th, 2026 5:30 am
Faeth selloff ‘disproportionate’ to data, says Lucid Capital
- Nov 9th, 2026 9:50 pm
Faeth Therapeutics Plummets 42%. What Investors Are Getting Wrong, According To Analysts.
- Nov 9th, 2026 2:19 pm
Top Midday Decliners
- Nov 9th, 2026 11:55 am
Faeth Therapeutics Reports 33% Response Rate in Phase 2 PIKTOR Trial for Advanced Endometrial Cancer
- Nov 9th, 2026 9:00 am
Faeth Therapeutics reports positive Phase 2 results for endometrial cancer drug
- Nov 9th, 2026 5:30 am
Faeth Reports Positive Preliminary Phase 2 Topline Results from the PIK-201 Trial Evaluating PIKTOR in Combination with Paclitaxel in Patients with Advanced Endometrial Cancer
- Nov 9th, 2026 5:00 am
Faeth to Report PIK-201 Phase 2 Data and Host Virtual Event on November 9, 2026
- Nov 6th, 2026 2:00 pm
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Nov 5th, 2026 2:05 pm
Faeth Therapeutics Reports Third Quarter 2026 Financial Results and Operational Updates
- Nov 3rd, 2026 5:30 am
Faeth Appoints Adam Schayowitz, Ph.D., MBA, Head of Research and Development at Zymeworks, to Board of Directors
- Oct 27th, 2026 5:00 am
Faeth Presents Updated Preclinical Data at ESMO, including First-Ever Head-to-Head Characterization of PIKTOR against Gedatolisib
- Oct 23rd, 2026 7:15 am
William Blair Expands Biotech Research as Veteran Analyst Alethia Young Initiates Coverage
- Oct 21st, 2026 10:30 am
Faeth to Present Preclinical Data on PIKTOR in HR+/HER2- Breast Cancer Models at ESMO 2026
- Oct 19th, 2026 5:30 am
Sensei Biotherapeutics Highlights PIKTOR Strategy Ahead of Endometrial Trial Readout
- Oct 7th, 2026 2:02 am
Faeth Therapeutics Appoints Karen Vousden, Ph.D., to Board of Directors
- Sep 17th, 2026 2:00 pm
Faeth Therapeutics to Host Virtual KOL Event on Multi-Nodal Inhibition for the Treatment of Endometrial Cancer on October 6, 2026
- Sep 8th, 2026 5:30 am
What Makes Faeth Therapeutics, Inc. (FTH) a Strong Momentum Stock: Buy Now?
- Sep 1st, 2026 10:00 am
Scroll